Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
25 January 2021 |
Main ID: |
NCT03268330 |
Date of registration:
|
29/08/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis
|
Scientific title:
|
Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis |
Date of first enrolment:
|
September 2021 |
Target sample size:
|
40 |
Recruitment status: |
Recruiting |
URL:
|
https://clinicaltrials.gov/show/NCT03268330 |
Study type:
|
Observational |
Study design:
|
|
Phase:
|
|
|
Countries of recruitment
|
Egypt
| | | | | | | |
Contacts
|
Name:
|
Naima M Omran, Resident |
Address:
|
|
Telephone:
|
+01008592039 |
Email:
|
heissa999@yahoo.com |
Affiliation:
|
|
|
Name:
|
Doaa K Mohamed, Lectruer |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Assiut University |
| |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
-Patients with Systemic Sclerosis .
Exclusion Criteria:
- Patients with Interstitial Pulmonary Fibrosis caused by causes other than SSc.
- Other rheumatologic diseases.
- Overlap or Mixed diseases.
- Patients with renal disease caused by causes other than SSc.
- Unwillingness to participate in the study.
Age minimum:
17 Years
Age maximum:
70 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
System; Sclerosis
|
Primary Outcome(s)
|
Correlation between Migration Inhibitory Factor and some of the clinical manifestations of Systemic Sclerosis.
[Time Frame: 1 hour]
|
Secondary ID(s)
|
ROMMIFISS
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|